Find and Pitch Jounalists, Get Your Story Covered

Tags: locally advanced or metastatic urothelial carcinoma ,metastatic urothelial carcinoma,antibody drug conjugate ,nectin-4 Locally Advanced or Metastatic Urothelial Carcinoma,antibody drug conjugate,PD-1/L1 inhibitor ,urothelial carcinomas

	Profile	Recent Articles on Subject
1	Tara Haelle MedPage Today Sci/health journalist. Feminist. Educator. Photographer. Author. DFW science journalismhealthphotographyteaching	Studies Point to Several Options for Ulcerative Colitis After Anti-TNF Failure - 11 days ago
2	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Phase 3 Trial Shows Promising Results for Encorafenib Combination Regimen for Patients with Metastatic Colorectal Cancer - 18 days ago Posdinemab Receives FDA Fast Track Designation for Treatment of Alzheimer Disease - about 2 months ago Avutometinib Plus Defactinib Moves One Step Closer to Approval for Treatment of Ovarian Cancer - about 2 months ago New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer - 7 months ago FDA Approves Durvalumab Plus Chemotherapy to Treat Endometrial Cancer - 8 months ago
3	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	FDA Approves Datroway for Pretreated Advanced Breast Cancer - about 1 month ago FDA Approves Zanidatamab for Biliary Tract Cancer - 3 months ago Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain Mets - 5 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 6 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 6 months ago A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu - 12 months ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - about 1 year ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - about 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - over 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - over 1 year ago Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer - over 1 year ago
4	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Sequencing in Advanced Urothelial Carcinoma - 4 months ago Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 8 months ago Are T-DXd Results in HER2-Low/Ultralow Breast Cancer Practice-Changing? - 8 months ago Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T - about 1 year ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - about 1 year ago Dato-DXd More Effective, Tolerable Than Chemo for Metastatic Breast Cancer - about 1 year ago T-DXd Could Be 'Practice-Changing' in HER2-Expressing Gynecologic Cancers - about 1 year ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - about 1 year ago
5	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 4 months ago
6	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	European Commission grants orphan drug designation for Vivet’s VTX-806 - 6 months ago
7	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - 6 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 6 months ago FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 8 months ago Brentuximab Vedotin Shows 37% Reduction in Risk of Death for DLBCL - 8 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 11 months ago FDA Grants Orphan Drug Designation to Felzartamab for Kidney Transplant Recipients - 11 months ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - 12 months ago Biogen Reprioritizes Alzheimer Disease Franchise, Discontinuing Aducanumab and Advancing Lecanemab - about 1 year ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - about 1 year ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - about 1 year ago FDA Grants Breakthrough Therapy Designation to Epcoritamab for Follicular Lymphoma - about 1 year ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - over 1 year ago Subcutaneous Lecanemab Demonstrates Greater Amyloid Plaque Removal Than Intravenous Lecanemab - over 1 year ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - over 1 year ago
8	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	AstraZeneca, Daiichi Sankyo Drug Enhertu Becomes First Tumor-Agnostic ADC Cancer Med - 11 months ago
9	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors - 11 months ago Subcutaneous Daratumumab Plus VRd Significantly Improved PFS, Increased Depth of Response in Patients With Newly Diagnosed Multiple Myeloma - about 1 year ago Phase 3 Study Supports Pembrolizumab Plus Lenvatinib as Standard of Care in Patients With Advanced Endometrial Cancer Who Received Prior Platinum Therapy - over 1 year ago
10	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 12 months ago Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial - about 1 year ago Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients - about 1 year ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - over 1 year ago Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years - over 1 year ago

Journalists covering enfortumab vedotin